2014
DOI: 10.1016/j.coph.2014.06.003
|View full text |Cite
|
Sign up to set email alerts
|

Development of GI-safe NSAID; progression from the bark of willow tree to modern pharmacology

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
12
0

Year Published

2015
2015
2023
2023

Publication Types

Select...
9

Relationship

2
7

Authors

Journals

citations
Cited by 19 publications
(13 citation statements)
references
References 46 publications
1
12
0
Order By: Relevance
“…The results of evaluation of gastric lesions after exposition to high dose of PMFA are in agreement with clinical studies where non-selective NSAI was compared with COX-2 inhibitors and the ulcer index was observed, suggesting that PMFA might act by a mechanism independent of COX-1 inhibition (Kangwan et al, 2014). Emphasizing this, in a previous study we demonstrated that PMFA has no effect on platelet aggregation in vitro (Verdam et al, 2009), which is dependent on action of this enzyme (Dovizio et al, 2014).…”
Section: Resultssupporting
confidence: 77%
“…The results of evaluation of gastric lesions after exposition to high dose of PMFA are in agreement with clinical studies where non-selective NSAI was compared with COX-2 inhibitors and the ulcer index was observed, suggesting that PMFA might act by a mechanism independent of COX-1 inhibition (Kangwan et al, 2014). Emphasizing this, in a previous study we demonstrated that PMFA has no effect on platelet aggregation in vitro (Verdam et al, 2009), which is dependent on action of this enzyme (Dovizio et al, 2014).…”
Section: Resultssupporting
confidence: 77%
“…In addition, efforts to obtain drugs able to inhibit both 5-lipoxygenase and COX, the so-called dualacting anti-inflammatory drugs [19], have continued because dual-acting anti-inflammatory drugs retain the activity of classic NSAIDs, while avoiding their main drawbacks [20]. Currently, various structural families of dual-acting anti-inflammatory drugs have been designed, and several compounds are under clinical investigation [21], although humans have taken almost 2,000 years to develop coxibs, starting from willow tree bark to the development of aspirin [22] (Figs. 1, 3).…”
Section: Safer Nsaids To Cover the Aforementioned Adverse Effectsmentioning
confidence: 99%
“…Currently, the main pharmacological treatment for this disease is antisecretory drugs including, histamine type 2 receptor antagonists such as cimetidine and congeners, and irreversible proton pump inhibitors such as omeprazole, famotidine and congeners. Although effective, long-term treatment with these drugs is associated with several side effects and poor gastric healing, leading to ulcer recurrence [ 9 ].…”
Section: Introductionmentioning
confidence: 99%